<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178148</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2018-02/CR-01</org_study_id>
    <nct_id>NCT04178148</nct_id>
  </id_info>
  <brief_title>Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock</brief_title>
  <acronym>AMINO BESTDOSE</acronym>
  <official_title>Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amikacin dose optimization is challenging in critically ill patients. The use of BestDose
      software algorithm-based drug optimization could help to achieve the recommended target
      concentrations (60-80 mg/L) after administration of the second dose of amikacin, associated
      with improved outcome. The study investigators hypothesize that 80% of patients undergoing
      drug dosing optimization using the BestDose software in the interventional group will reach
      the predefined PK/PD targets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients reaching target amikacin maximum concentration following second dose</measure>
    <time_frame>30 minutes after second dose of amikacin</time_frame>
    <description>Yes/no; Cmax 60-80mg/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients reaching target amikacin minimum concentration following second dose</measure>
    <time_frame>24 hours after second dose of amikacin</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients reaching target amikacin maximum concentration following third dose</measure>
    <time_frame>30 minutes after third dose of amikacin</time_frame>
    <description>Yes/no; Cmax 60-80mg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients reaching target amikacin minimum concentration following third dose</measure>
    <time_frame>24 hours after third dose of amikacin</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to reach recommended Cmax during amikacin therapy</measure>
    <time_frame>Maximum 7 days</time_frame>
    <description>Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure test</measure>
    <time_frame>At end of treatment (Maximum day 7)</time_frame>
    <description>Either clinical-evaluated or assessed according to patient medical files: classified as resolved, improved, failed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure test</measure>
    <time_frame>Day 7</time_frame>
    <description>Either clinical-evaluated or assessed according to patient medical files: classified as resolved, improved, failed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without renal replacement therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without vasopressors</measure>
    <time_frame>Day 28</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>BestDose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic drug optimization of amikacin using the BestDose software algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amikacin dose optimization</intervention_name>
    <description>Therapeutic drug optimization of amikacin using the BestDose software algorithm</description>
    <arm_group_label>BestDose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient or their legal representative must have given their free and informed
             consent and signed the consent form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient has septic shock according to the SEPSIS-3 definition in the 24 hours
             preceding inclusion, regardless of the source of infection

          -  Patient having already received a first dose of amikacin in the 22 preceding hours

          -  Patient with an expectation of receiving at least 2 doses of amikacin

          -  Patient with available amikacin therapeutic drug monitoring

        Exclusion Criteria:

          -  The subject is participating in an interventional study that could influence the
             primary outcome, or is in a period of exclusion determined by a previous study

          -  The patient is pregnant, parturient or breastfeeding

          -  Patient has a contra-indication or an allergy to treatment by amikacin

          -  Patient is not expected to survive beyond 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Roger</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Roger, MD</last_name>
    <phone>04.66.68.30.50</phone>
    <email>Claire.roger@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Roger</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Martiniere</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Yves Lefrant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Louart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>dose optimisation</keyword>
  <keyword>aminoglycosides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

